Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pregnancy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,882 result(s) found for: Pregnancy. Displaying page 174 of 545.
    EudraCT Number: 2014-004078-40 Sponsor Protocol Number: CQR14002 Start Date*: 2015-01-28
    Sponsor Name:CeQur Corp.
    Full Title: A Prospective, Single Center, Observational Study to Assess the Performance, Safety, and Patient Reported Outcomes of Insulin Delivery with PaQ® in Patients with Type 2 Diabetes Mellitus
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10053247 Insulin-requiring type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001911-31 Sponsor Protocol Number: 30032006 Start Date*: 2007-06-27
    Sponsor Name:Universitätsfrauenklinik Innsbruck
    Full Title: Metformin-Wirkung am Ovar bei PCOS (MAO-Studie) - eine Pilotstudie
    Medical condition: Polycystic ovary syndrome is one of the most common endocrine disorders, affecting approximately 10% of women of reproductive age, associated with hyperandrogenaemia and menstrual dysfunction. The ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014695 Endocrine disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000181-21 Sponsor Protocol Number: BUCSU Start Date*: 2014-07-02
    Sponsor Name:Charite - Universitätsmedizin Berlin
    Full Title: Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003638-28 Sponsor Protocol Number: 2015/576 Start Date*: 2015-09-30
    Sponsor Name:Aarhus University Hospital
    Full Title: ALOSTRA Alendronate treatment of osteoporosis in rheumatoid arthritis – indication and duration. A randomized, doubleblind, placebocontrolled multi-centre study to evaluate the effects of disconti...
    Medical condition: Rheumatoid arthritis and osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10031289 Osteoporosis, unspecified LLT
    20.0 100000004859 10039076 Rheumatoid arthritis and other inflammatory polyarthropathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003089-16 Sponsor Protocol Number: AGO-OVAR2.11 Start Date*: 2007-08-31
    Sponsor Name:AGO Research GmbH
    Full Title: Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine k...
    Medical condition: Platinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015904-24 Sponsor Protocol Number: UKB-2009-MED-I-JKR-01 Start Date*: 2010-10-20
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection i...
    Medical condition: HIV disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003257-20 Sponsor Protocol Number: 10MI28 Start Date*: 2014-05-02
    Sponsor Name:GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST
    Full Title: Evaluation of Treosulfan pharmacokinetics (PK) in children undergoing allogeneic haematopoietic stem cell transplantation (HSCT)
    Medical condition: Any paediatric disease with an indication to an allogeneic stem cell transplantation (inclusing leukaemia, primary immunodeficiencies, metabolic disorders and autoimmune or genetic inflammatory bow...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001198-55 Sponsor Protocol Number: KronLungesyg_COVID_19_protokol_2 Start Date*: 2020-04-03
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID
    Medical condition: This trial will investigate infection with coronavirus (COVID-19) in patients who are admitted to hospital
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003127-62 Sponsor Protocol Number: MuSK-001 Start Date*: 2015-10-02
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with MuSK Antibody Positive Myasthenia Gravis
    Medical condition: Patients with MuSK Antibody Positive Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10062976 Neuromuscular weakness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020063-21 Sponsor Protocol Number: ILUVIT1 Start Date*: 2010-06-15
    Sponsor Name:Charité-Universitätsmedizin
    Full Title: “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”
    Medical condition: Urticarial vasculitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048820 Urticarial vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014844-13 Sponsor Protocol Number: 50-2009 Start Date*: 2010-03-16
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantat...
    Medical condition: Treatment ot mantle cell lymphoma patients in first or second relapse or refractory disease. Patients should not be eligible for high dose chemotherapy with autologous or allogenous stem cell trans...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003553-42 Sponsor Protocol Number: AIO-HEP-0217 Start Date*: 2018-05-03
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)
    Medical condition: intermediate stage hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077738 Hepatocellular carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004963-32 Sponsor Protocol Number: MPR-2 Start Date*: 2005-07-18
    Sponsor Name:Univ. Prof. Dr. Markus Peck-Radosavljevic
    Full Title: Bevacizumab (Avastin®) as inhibitor of collateral tumor vessel growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC): a pilot trial
    Medical condition: Hepatocellular Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004561-33 Sponsor Protocol Number: ThromboAct Start Date*: 2014-05-23
    Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin III, Abteilung für Gastroenterologie und Hepatologie
    Full Title: A randomized, controlled, single-blinded, phase II study to investigate the safety and efficacy of intravenous infusions of FERINJECT® versus placebo on platelet activity in patients with iron defi...
    Medical condition: iron deficiency in chronic inflammatory bowel disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002095-18 Sponsor Protocol Number: 107731 Start Date*: 2007-03-20
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II randomized, double-blind (observer blind), adjuvant justification study of RTS,S/AS01B and RTS,S/AS02A, candidate malaria vaccines, administered according to a 0, 1, 2 months schedule in...
    Medical condition: Malaria disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006144-55 Sponsor Protocol Number: ARD6123 [AVE0005B/2001] Start Date*: 2007-03-14
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant,...
    Medical condition: patients with platinum- and erlotinib-resistant, locally advanced or metastatic non-small-cell lung adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005463-10 Sponsor Protocol Number: PLQ-001 Start Date*: 2008-02-06
    Sponsor Name:LEO Pharma A/S
    Full Title: A plaque test comparing three marketed products and two products in development and a vehicle control for the treatment of psoriasis vulgaris
    Medical condition: Psoriasis vulgaris lesions located on the arms, legs or trunk.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005487-13 Sponsor Protocol Number: PLQ-002 Start Date*: 2008-12-30
    Sponsor Name:LEO Pharma A/S
    Full Title: A plaque test comparing 4 steroids with Daivobet® ointment and a vehicle control for the treatment of psoriasis vulgaris
    Medical condition: Psoriasis vulgaris lesions located on the arms, legs or trunk.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007888-24 Sponsor Protocol Number: 0881X1-4508-FR Start Date*: 2008-07-31
    Sponsor Name:Wyeth Pharmaceuticals France
    Full Title: Open-label Study to Evaluate the EULAR-RAID Score, Rheumatoid Arthritis Impact of Disease Score, in Rheumatoid Arthritis Patients Eligible to Etanercept and Who Will Receive Etanercept.
    Medical condition: RHEUMATOID ARTHRITIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001012-68 Sponsor Protocol Number: CA182-006 Start Date*: 2007-04-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients...
    Medical condition: Unresectable, advanced or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:27:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA